KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Liabilities (2016 - 2025)

Neogenomics' Total Liabilities history spans 16 years, with the latest figure at $523.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 28.87% year-over-year to $523.3 million; the TTM value through Dec 2025 reached $523.3 million, down 28.87%, while the annual FY2025 figure was $523.3 million, 28.87% down from the prior year.
  • Total Liabilities reached $523.3 million in Q4 2025 per NEO's latest filing, down from $536.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $769.1 million in Q3 2021 to a low of $523.3 million in Q4 2025.
  • Average Total Liabilities over 5 years is $704.3 million, with a median of $735.2 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 186.39% in 2021, then decreased 28.87% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $761.5 million in 2021, then decreased by 2.56% to $742.0 million in 2022, then decreased by 0.31% to $739.7 million in 2023, then dropped by 0.54% to $735.7 million in 2024, then fell by 28.87% to $523.3 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Total Liabilities are $523.3 million (Q4 2025), $536.5 million (Q3 2025), and $539.9 million (Q2 2025).